Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results

被引:16
|
作者
Lambrecht, Marie [1 ,3 ]
Clementel, Enrico [2 ]
Sonke, Jan-Jacob [3 ]
Nestle, Ursula [4 ,5 ]
Adebahr, Sonja [5 ,6 ,7 ]
Guckenberger, Mathias [8 ]
Andratschke, Nicolaus [8 ]
Weber, Damien C. [8 ,9 ]
Verheij, Marcel [3 ]
Hurkmans, Coen W. [1 ]
机构
[1] Catharina Hosp, Dept Radiat Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] EORTC Headquarters, Dept Qual Assurance, Brussels, Belgium
[3] Netherland Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Kliniken Maria Hilf GmbH Monchengladbach, Dept Radiat Oncol, Monchengladbach, Germany
[5] Univ Freiburg, Fac Med, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[6] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[9] Paul Scherrer Inst, ETH Domain, Ctr Proton Therapy, Villigen, Switzerland
关键词
Benchmark; SBRT; Lung; Planning exercise; Clinical trial; RADIATION; ATLAS;
D O I
10.1016/j.radonc.2018.10.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report on the benchmark case (BC) study performed in the context of the European Organisation for Research and Treatment of Cancer prospective multicentre Lungtech trial of SBRT for patients with inoperable centrally located lung tumours. Methods and materials: Target volume and organs at risk (OARs) delineations first needed to be acceptable before the treatment plan was reviewed. Retrospectively, Dice similarity coefficients of the OARs and the target volumes were calculated and a set of gold standard contours adapted for each institution margins was applied on the accepted dose submissions to evaluate the influence of acceptable delineation variations on dosimetry. Results: Twenty-five institutions participated. Five BCs were accepted at the first attempt. Twenty institutions had to revise their delineation at least once and seven had to revise their planning once. The V-60 Gy dose coverage improved significantly (p = 0.05) between the first and final submissions from median (range) 94.8% (22.5-97.8) to 95.3% (70.5-99.3). The median Dice coefficient varied significantly between OARs: The lowest values were found for the brachial plexus 0.25 (0.01-0.54) and the highest for the spinal cord 0.89 (0.71-0.95). The mean PTV Dice coefficient was 0.82 (0.48-0.92). Applying the gold standard contours, only one institution remained compliant with the dose coverage criteria with V-60 Gy median (range) of 83.4% (54.2-93.9). Conclusions: Clinical guidelines and radiotherapy protocols are not a substitute for timely radiotherapy quality assurance procedures, which improve dose coverage significantly. Delineation remains the main source of BC rejection and plan review without first reviewing delineation may not be efficient. Our results show that delineation variations seem to have a larger influence on PTV coverage than variations in planning and irradiation techniques and thus suggest that dose tolerance criteria should preferably take into account the accuracy of delineation. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [31] Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy
    Kramer, Gijsbert W. P. M.
    Legrand, Catherine L.
    van Schil, Paul
    Uitterhoeve, Lon
    Smit, Egbert F.
    Schramel, Franz
    Biesma, Bonne
    Tjan-Heijnen, Vivianne
    van Zandwijk, Nico
    Splinter, Ted
    Giaccone, Giuseppe
    van Meerbeeck, Jan P.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1391 - 1398
  • [32] Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case
    Song, Yu-Chun
    Hu, Zhi-Hui
    Yan, Xue-Na
    Fang, Hui
    Tang, Yu
    Jing, Hao
    Men, Kuo
    Zhang, Na
    Zhang, Jun
    Jin, Jing
    Zhong, Qiu-Zi
    Ma, Jun
    Yang, Wei-Fang
    Zhong, Ya-Hua
    Dong, Li-Hua
    Wang, Xiao-Hong
    Wu, Hong-Fen
    Du, Xiang-Hui
    Hou, Xiao-Rong
    Tie, Jian
    Lu, Yu-Fei
    Zhao, Li-Na
    Li, Ye-Xiong
    Wang, Shu-Lian
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [33] Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case
    Yu-Chun Song
    Zhi-Hui Hu
    Xue-Na Yan
    Hui Fang
    Yu Tang
    Hao Jing
    Kuo Men
    Na Zhang
    Jun Zhang
    Jing Jin
    Qiu-Zi Zhong
    Jun Ma
    Wei-Fang Yang
    Ya-Hua Zhong
    Li-Hua Dong
    Xiao-Hong Wang
    Hong-Fen Wu
    Xiang-Hui Du
    Xiao-Rong Hou
    Jian Tie
    Yu-Fei Lu
    Li-Na Zhao
    Ye-Xiong Li
    Shu-Lian Wang
    Radiation Oncology, 18
  • [34] Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
    Stupp, Roger
    Mayer, Michael
    Kann, Roger
    Weder, Walter
    Zouhair, Abderahim
    Betticher, Daniel C.
    Roth, Arnaud D.
    Stahel, Rolf A.
    Majno, Sabine Balmer
    Peters, Solange
    Jost, Lorenz
    Furrer, Markus
    Thierstein, Sandra
    Schmid, Ralph A.
    Hsu-Schmitz, Shu-Fong
    Mirimanoff, Rene-Olivier
    Ris, Hans-Beat
    Pless, Miklos
    LANCET ONCOLOGY, 2009, 10 (08): : 785 - 793
  • [35] Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre phase II trial
    Van Kooten M.
    Traine G.
    Cinat G.
    Cazap E.
    Zori Comba A.
    Vicente H.
    Sena S.
    Rodriguez Nievas O.
    Orlando M.
    British Journal of Cancer, 1999, 81 (5) : 846 - 849
  • [36] Experiences of pre-trial quality assurance (QA) for the CONVERT trial. A multicentre randomised phase III trial for good performance status patients with limited stage small cell lung cancer
    Wilson, E.
    Groom, N.
    Lyn, E.
    Miles, E.
    Tsang, Y.
    Faivre-Finn, C.
    LUNG CANCER, 2012, 75 : S55 - S56
  • [37] EXPERIENCES OF PRE-TRIAL QUALITY ASSURANCE (QA) FOR THE CONVERT TRIAL. A MULTICENTRE RANDOMISED PHASE III TRIAL FOR GOOD PERFORMANCE STATUS PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER
    Groom, Nicki
    Wilson, Elena
    Lyn, Ethan B.
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S812 - S813
  • [38] Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours
    Hoffmann, L.
    Persson, G. F.
    Nygard, L.
    Nielsen, T. B.
    Borrisova, S.
    Gaard-Petersen, F.
    Josipovic, M.
    Khalil, A. A.
    Kjeldsen, R.
    Knap, M. M.
    Kristiansen, C.
    Moller, D. S.
    Ottosson, W.
    Sand, H.
    Thing, R.
    Pohl, M.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2022, 171 : 53 - 61
  • [39] Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase II RTCMIENDOMETRE French multicentre trial
    Barillot, Isabelle
    Tavernier, Elsa
    Peignaux, Karine
    Williaume, Daniele
    Nickers, Philippe
    Leblanc-Onfroy, Magali
    Lerouge, Delphine
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 (01) : 138 - 143
  • [40] Quality assurance (QA) in a UK randomised controlled trial (RCT) of radiotherapy in patients with stage I-II now small cell lung cancer (NSCLC) unfit for surgery
    Mohammed, N.
    Erridge, S.
    McEleney, T.
    Price, A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S467 - S467